Steven F G Jeuring1, Paul H A Bours2, Maurice P Zeegers3, Ton W Ambergen4, Tim R A van den Heuvel2, Mariëlle J L Romberg-Camps5, Ad A van Bodegraven5, Liekele E Oostenbrug6, Stéphanie O Breukink7, Laurents P S Stassen7, Wim H Hameeteman2, Ad A M Masclee2, Daisy M A E Jonkers2, Marieke J Pierik2. 1. Division of Gastroenterology-Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands School of Nutrition and Translational Research in Metabolism [NUTRIM], Maastricht University Medical Centre+, Maastricht, The Netherlands steven.jeuring@maastrichtuniversity.nl. 2. Division of Gastroenterology-Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands School of Nutrition and Translational Research in Metabolism [NUTRIM], Maastricht University Medical Centre+, Maastricht, The Netherlands. 3. Department of Complex Genetics, School of Nutrition and Translational Research in Metabolism [NUTRIM], Maastricht University Medical Centre+, Maastricht, The Netherlands. 4. Department of Methodology and Statistics, Maastricht University Medical Centre+, Maastricht, The Netherlands. 5. Department of Internal Medicine and Gastroenterology, Orbis Medical Centre, Sittard-Geleen, The Netherlands. 6. Department of Internal Medicine and Gastroenterology, Atrium Medical Centre, Heerlen, The Netherlands. 7. Department of General Surgery, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Abstract
BACKGROUND AND AIMS: In the past decades, treatment options and strategies for ulcerative colitis [UC] have radically changed. Whether these developments have altered the disease outcome at population level is yet unknown. Therefore, we evaluated the disease outcome of UC over the past two decades in the South-Limburg area of The Netherlands. METHODS: In the Dutch population-based IBDSL cohort, three time cohorts were defined: cohort 1991-1997 [cohort A], cohort 1998-2005 [cohort B], and cohort 2006-2010 [cohort C]. The colectomy and hospitalisation rates were compared between cohorts by Kaplan-Meier survival analyses. Hazard ratios [HR] for early colectomy [within 6 months after diagnosis], late colectomy [beyond 6 months after diagnosis], and hospitalisation were calculated using Cox regression models. RESULTS: In total, 476 UC patients were included in cohort A, 587 patients in cohort B, and 598 patients in cohort C. Over time, an increase in the use of immunomodulators [8.1%, 22.8% and 21.7%, respectively, p < 0.01] and biological agents [0%, 4.3% and 10.6%, respectively, p < 0.01] was observed. The early colectomy rate decreased from 1.5% in cohort A to 0.5% in cohort B [HR 0.14; 95% confidence interval 0.04-0.47], with no further decrease in cohort C [0.3%, HR 0.98; 95% confidence interval 0.20-4.85]. Late colectomy rate remained unchanged over time [4.0% vs 5.2% vs 3.6%, respectively, p = 0.54]. Hospitalisation rate was also similar among cohorts [22.3% vs 19.5% vs 18.3%, respectively, p = 0.10]. CONCLUSION: Over the past two decades, a reduction in early colectomy rate was observed, with no further reduction in the most recent era. Late colectomy rate and hospitalisation rate remained unchanged over time.
BACKGROUND AND AIMS: In the past decades, treatment options and strategies for ulcerative colitis [UC] have radically changed. Whether these developments have altered the disease outcome at population level is yet unknown. Therefore, we evaluated the disease outcome of UC over the past two decades in the South-Limburg area of The Netherlands. METHODS: In the Dutch population-based IBDSL cohort, three time cohorts were defined: cohort 1991-1997 [cohort A], cohort 1998-2005 [cohort B], and cohort 2006-2010 [cohort C]. The colectomy and hospitalisation rates were compared between cohorts by Kaplan-Meier survival analyses. Hazard ratios [HR] for early colectomy [within 6 months after diagnosis], late colectomy [beyond 6 months after diagnosis], and hospitalisation were calculated using Cox regression models. RESULTS: In total, 476 UC patients were included in cohort A, 587 patients in cohort B, and 598 patients in cohort C. Over time, an increase in the use of immunomodulators [8.1%, 22.8% and 21.7%, respectively, p < 0.01] and biological agents [0%, 4.3% and 10.6%, respectively, p < 0.01] was observed. The early colectomy rate decreased from 1.5% in cohort A to 0.5% in cohort B [HR 0.14; 95% confidence interval 0.04-0.47], with no further decrease in cohort C [0.3%, HR 0.98; 95% confidence interval 0.20-4.85]. Late colectomy rate remained unchanged over time [4.0% vs 5.2% vs 3.6%, respectively, p = 0.54]. Hospitalisation rate was also similar among cohorts [22.3% vs 19.5% vs 18.3%, respectively, p = 0.10]. CONCLUSION: Over the past two decades, a reduction in early colectomy rate was observed, with no further reduction in the most recent era. Late colectomy rate and hospitalisation rate remained unchanged over time.
Authors: Steven F G Jeuring; Vince B C Biemans; Tim R A van den Heuvel; Maurice P Zeegers; Wim H Hameeteman; Mariëlle J L Romberg-Camps; Liekele E Oostenbrug; Ad A M Masclee; Daisy M A E Jonkers; Marieke J Pierik Journal: Am J Gastroenterol Date: 2018-01-09 Impact factor: 10.864
Authors: Edward L Barnes; Yue Jiang; Michael D Kappelman; Millie D Long; Robert S Sandler; Alan C Kinlaw; Hans H Herfarth Journal: Inflamm Bowel Dis Date: 2020-07-17 Impact factor: 5.325
Authors: S Sahami; K Konté; C J Buskens; P J Tanis; M Löwenberg; C J Ponsioen; G R van den Brink; W A Bemelman; G R D'Haens Journal: United European Gastroenterol J Date: 2016-11-25 Impact factor: 4.623
Authors: David Marti-Aguado; María Pilar Ballester; Joan Tosca; Marta Maia Bosca-Watts; Pablo Navarro; Rosario Anton; Isabel Pascual; Francisco Mora; Miguel Minguez Journal: United European Gastroenterol J Date: 2019-05-29 Impact factor: 4.623
Authors: Christopher Ma; Jenny Jeyarajah; Leonardo Guizzetti; Claire E Parker; Siddharth Singh; Parambir S Dulai; Geert R D'Haens; William J Sandborn; Brian G Feagan; Vipul Jairath Journal: Clin Gastroenterol Hepatol Date: 2020-12-03 Impact factor: 11.382